MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 مناظر
• 07/09/23
0
0
ایمبیڈ
administrator
سبسکرائبرز
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
مزید دکھائیں
فیس بک کے تبصرے
SORT BY-
سرفہرست تبصرے
-
تازہ ترین تبصرے